aTyr Pharma’s (LIFE) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of aTyr Pharma (NASDAQ:LIFE) in a research note released on Friday morning, Benzinga reports. The brokerage currently has a $35.00 price objective on the biotechnology company’s stock.

Several other research firms have also issued reports on LIFE. StockNews.com lowered aTyr Pharma from a hold rating to a sell rating in a research report on Saturday, December 16th. Royal Bank of Canada dropped their price target on aTyr Pharma from $19.00 to $16.00 and set an outperform rating on the stock in a research report on Friday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, aTyr Pharma has an average rating of Hold and a consensus price target of $23.67.

aTyr Pharma Stock Performance

Shares of LIFE stock traded down $0.03 on Friday, hitting $1.96. 866,872 shares of the stock traded hands, compared to its average volume of 541,899. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.33 and a quick ratio of 8.33. The company has a market capitalization of $114.48 million, a PE ratio of -2.04 and a beta of 1.25. aTyr Pharma has a 1-year low of $1.08 and a 1-year high of $2.70. The company’s fifty day moving average is $1.73 and its 200 day moving average is $1.50.

Institutional Investors Weigh In On aTyr Pharma

Several large investors have recently added to or reduced their stakes in LIFE. Granite Bay Wealth Management LLC acquired a new stake in aTyr Pharma in the fourth quarter worth $25,000. Squarepoint Ops LLC acquired a new stake in aTyr Pharma in the first quarter worth $26,000. Two Sigma Securities LLC acquired a new stake in aTyr Pharma in the second quarter worth $26,000. Jane Street Group LLC acquired a new stake in aTyr Pharma in the second quarter worth $29,000. Finally, American Century Companies Inc. grew its stake in shares of aTyr Pharma by 55.6% in the third quarter. American Century Companies Inc. now owns 22,080 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 7,889 shares in the last quarter. 62.53% of the stock is owned by institutional investors and hedge funds.

About aTyr Pharma

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.